Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

Clinical trial NCT05366855 · TERMINATED

Trial details

NCT number: NCT05366855
Sponsor: Vanda Pharmaceuticals
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Generalized Pustular Psoriasis

Start date: 2022-04-21
Primary completion: 2024-07-12
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.